Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

rhythm pharmaceuticals inc - RYTM

RYTM

Close Chg Chg %
110.00 2.55 2.32%

Closed Market

112.55

+2.55 (2.32%)

Volume: 571.47K

Last Updated:

Dec 29, 2025, 4:00 PM EDT

Trade Now

Company Overview: rhythm pharmaceuticals inc - RYTM

RYTM Key Data

Open

$109.81

 Day Range

107.88 - 112.72

52 Week Range

45.91 - 122.20

 Market Cap

$7.34B

Shares Outstanding

66.74M

 Public Float

62.33M

Beta

1.97

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$3.10

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

982.46K

  

RYTM Performance

1 Week
 
 0.00%
 
1 Month
 
 0.83%
 
3 Months
 
 11.09%
 
1 Year
 
 97.88%
 
5 Years
 
 270.00%
 

RYTM Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 15
Full Ratings ➔

About rhythm pharmaceuticals inc - RYTM

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

RYTM At a Glance

Rhythm Pharmaceuticals, Inc.
222 Berkeley Street
Boston, Massachusetts 02116-3748
Phone 1-857-264-4280 Revenue 130.13M
Industry Pharmaceuticals: Major Net Income -260,602,000.00
Sector Health Technology 2024 Sales Growth 68.061%
Fiscal Year-end 12 / 2025 Employees 283
View SEC Filings

RYTM Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 26.24
Price to Book Ratio 160.737
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -12.694
Enterprise Value to Sales 25.748
Total Debt to Enterprise Value 0.077

RYTM Efficiency

Revenue/Employee 459,809.187
Income Per Employee -920,855.124
Receivables Turnover 7.029
Total Asset Turnover 0.358

RYTM Liquidity

Current Ratio 3.239
Quick Ratio 3.077
Cash Ratio 2.775

RYTM Profitability

Gross Margin 89.183
Operating Margin -204.035
Pretax Margin -200.003
Net Margin -200.269
Return on Assets -71.77
Return on Equity -272.186
Return on Total Capital -93.642
Return on Invested Capital -94.225

RYTM Capital Structure

Total Debt to Total Equity 1,180.763
Total Debt to Total Capital 92.192
Total Debt to Total Assets 65.206
Long-Term Debt to Equity 1,173.671
Long-Term Debt to Total Capital 91.638
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Rhythm Pharmaceuticals Inc - RYTM

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
3.15M 23.64M 77.43M 130.13M
Sales Growth
- +649.46% +227.56% +68.06%
Cost of Goods Sold (COGS) incl D&A
1.42M 3.03M 10.21M 14.08M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.16M 1.40M 1.76M 1.56M
Depreciation
816.00K 629.00K 903.00K 708.00K
Amortization of Intangibles
342.00K 774.00K 855.00K 855.00K
COGS Growth
+105.07% +114.06% +236.91% +37.93%
Gross Income
1.74M 20.61M 67.22M 116.05M
Gross Income Growth
+352.03% +1,085.11% +226.18% +72.63%
Gross Profit Margin
+55.14% +87.19% +86.82% +89.18%
2021 2022 2023 2024 5-year trend
SG&A Expense
171.80M 199.77M 251.58M 381.55M
Research & Development
103.31M 107.73M 134.05M 237.25M
Other SG&A
68.49M 92.03M 117.53M 144.30M
SGA Growth
+26.43% +16.28% +25.94% +51.66%
Other Operating Expense
- - - -
-
Unusual Expense
- (250.00K) (190.00K) (7.48M)
EBIT after Unusual Expense
(170.06M) (178.91M) (184.17M) (258.02M)
Non Operating Income/Expense
100.45M 2.99M 13.95M 18.37M
Non-Operating Interest Income
447.00K 4.03M 13.95M 14.71M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- 5.20M 13.89M 20.60M
Interest Expense Growth
- - +167.10% +48.31%
-
Gross Interest Expense
- 5.20M 13.89M 20.60M
Interest Capitalized
- - - -
-
Pretax Income
(69.61M) (181.12M) (184.11M) (260.26M)
Pretax Income Growth
+48.05% -160.18% -1.65% -41.36%
Pretax Margin
-2,207.10% -766.22% -237.79% -200.00%
Income Tax
- - 564.00K 346.00K
-
Income Tax - Current - Domestic
- - - 1.00K
-
Income Tax - Current - Foreign
- - 563.00K 346.00K
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(69.61M) (181.12M) (184.68M) (260.60M)
Minority Interest Expense
- - - -
-
Net Income
(69.61M) (181.12M) (184.68M) (260.60M)
Net Income Growth
+48.05% -160.18% -1.97% -41.11%
Net Margin Growth
-2,207.10% -766.22% -238.52% -200.27%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(69.61M) (181.12M) (184.68M) (260.60M)
Preferred Dividends
- - - 3.97M
-
Net Income Available to Common
(69.61M) (181.12M) (184.68M) (264.57M)
EPS (Basic)
-1.4035 -3.475 -3.2022 -4.3376
EPS (Basic) Growth
+53.78% -147.60% +7.85% -35.46%
Basic Shares Outstanding
49.60M 52.12M 57.67M 61.00M
EPS (Diluted)
-1.4035 -3.475 -3.2022 -4.3376
EPS (Diluted) Growth
+53.78% -147.60% +7.85% -35.46%
Diluted Shares Outstanding
49.60M 52.12M 57.67M 61.00M
EBITDA
(168.90M) (177.75M) (182.60M) (263.94M)
EBITDA Growth
-24.30% -5.24% -2.73% -44.55%
EBITDA Margin
-5,355.14% -751.98% -235.83% -202.83%

Snapshot

Average Recommendation BUY Average Target Price 138.071
Number of Ratings 15 Current Quarters Estimate -0.822
FY Report Date 12 / 2025 Current Year's Estimate -3.168
Last Quarter’s Earnings -0.82 Median PE on CY Estimate N/A
Year Ago Earnings -4.34 Next Fiscal Year Estimate -2.686
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 14 9 14 14
Mean Estimate -0.82 -0.82 -3.17 -2.69
High Estimates -0.69 -0.67 -2.70 -1.93
Low Estimate -0.96 -1.03 -3.34 -3.65
Coefficient of Variance -10.75 -16.79 -5.03 -21.17

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 14 14 14
OVERWEIGHT 0 0 0
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Rhythm Pharmaceuticals Inc - RYTM

Date Name Shares Transaction Value
Mar 25, 2025 Christopher German Corporate Controller & CAO 3,233 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 25, 2025 Christopher German Corporate Controller & CAO 2,889 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $54.23 per share 156,670.47
Mar 25, 2025 Christopher German Corporate Controller & CAO 2,324 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 21, 2025 Yann Mazabraud EVP, Head of International 25,000 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 21, 2025 Yann Mazabraud EVP, Head of International 40,370 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $51.72 per share 2,087,936.40
Mar 21, 2025 Yann Mazabraud EVP, Head of International 96,173 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $50.79 per share 4,884,626.67
Mar 21, 2025 Yann Mazabraud EVP, Head of International 115,370 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $22.28 per share 2,570,443.60
Feb 20, 2025 Hunter C. Smith Chief Financial Officer 112,144 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 Hunter C. Smith Chief Financial Officer 19,800 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 Hunter C. Smith Chief Financial Officer 62,500 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 Hunter C. Smith Chief Financial Officer 41,650 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 Hunter C. Smith Chief Financial Officer 109,929 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $57.22 per share 6,290,137.38
Feb 20, 2025 Christopher German Corporate Controller & CAO 5,418 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 David P. Meeker President and CEO; Director 63,750 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 David P. Meeker President and CEO; Director 200,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 David P. Meeker President and CEO; Director 133,350 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 David P. Meeker President and CEO; Director 211,177 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 Jennifer L. Chien EVP, Head of North America 16,500 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 Jennifer L. Chien EVP, Head of North America 55,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 Jennifer L. Chien EVP, Head of North America 36,650 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Rhythm Pharmaceuticals Inc in the News